Huann-Sheng Chen

Huann-Sheng Chen

Auto-generated profile, based on publicly available information

Huann-Sheng Chen

Division of Cancer Control and Population Sciences, National Cancer Institute , Rockville, MD

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2022 in Statistics in Medicine
Verified
Journal Article
Closed access
HKHyune‐Ju Kim
Hyune‐Ju Kim
HCHuann‐Sheng Chen
Huann‐Sheng Chen
JBJeffrey Byrne
Jeffrey Byrne
BWBill Wheeler
Bill Wheeler
EFEric J. Feuer
Eric J. Feuer

24 June 2004 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
HJHongying Jiang
Hongying Jiang
YDYouping Deng
Youping Deng
HCHuann-Sheng Chen
Huann-Sheng Chen
LTLin Tao
Lin Tao
QSQiuying Sha
Qiuying Sha
SZShuanglin Zhang
Shuanglin Zhang
Due to the high cost and low reproducibility of many microarray experiments, it is not surprising to find a limited number of patient samples in each study, and very few common identified marker genes among different studies involving patients with the same disease. Therefore, it is of great interest and challenge to merge data sets from multiple studies to increase the sample size, which may in turn increase the power of statistical inferences. In this study, we combined two lung cancer studies using micorarray GeneChip®, employed two gene shaving methods and a two-step survival test to identify genes with expression patterns that can distinguish diseased from normal samples, and to indicate patient survival, respectively. In addition to common data transformation and normalization procedures, we applied a distribution transformation method to integrate the two data sets. Gene shaving (GS) methods based on Random Forests (RF) and Fisher's Linear Discrimination (FLD) were then applied separately to the joint data set for cancer gene selection. The two methods discovered 13 and 10 marker genes (5 in common), respectively, with expression patterns differentiating diseased from normal samples. Among these marker genes, 8 and 7 were found to be cancer-related in other published reports. Furthermore, based on these marker genes, the classifiers we built from one data set predicted the other data set with more than 98% accuracy. Using the univariate Cox proportional hazard regression model, the expression patterns of 36 genes were found to be significantly correlated with patient survival (p < 0.05). Twenty-six of these 36 genes were reported as survival-related genes from the literature, including 7 known tumor-suppressor genes and 9 oncogenes. Additional principal component regression analysis further reduced the gene list from 36 to 16. This study provided a valuable method of integrating microarray data sets with different origins, and new methods of selecting a minimum number of marker genes to aid in cancer diagnosis. After careful data integration, the classification method developed from one data set can be applied to the other with high prediction accuracy.

5 June 2017 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
HKHyune‐Ju Kim
Hyune‐Ju Kim
JLJun Luo
Jun Luo
HCHuann‐Sheng Chen
Huann‐Sheng Chen
DGDon Green
Don Green
DBDennis Buckman
Dennis Buckman
EFEric J. Feuer
Eric J. Feuer

30 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKSapna Kumari
Sapna Kumari
JNJeff Nie
Jeff Nie
HCHuann-Sheng Chen
Huann-Sheng Chen
Hao MaHao Ma
Hao Ma
RSRon Stewart
Ron Stewart
HWHairong Wei
Hairong Wei
Constructing coexpression networks and performing network analysis using large-scale gene expression data sets is an effective way to uncover new biological knowledge; however, the methods used for gene association in constructing these coexpression networks have not been thoroughly evaluated. Since different methods lead to structurally different coexpression networks and provide different information, selecting the optimal gene association method is critical. In this study, we compared eight gene association methods – Spearman rank correlation, Weighted Rank Correlation, Kendall, Hoeffding's D measure, Theil-Sen, Rank Theil-Sen, Distance Covariance, and Pearson – and focused on their true knowledge discovery rates in associating pathway genes and construction coordination networks of regulatory genes. We also examined the behaviors of different methods to microarray data with different properties, and whether the biological processes affect the efficiency of different methods. We found that the Spearman, Hoeffding and Kendall methods are effective in identifying coexpressed pathway genes, whereas the Theil-sen, Rank Theil-Sen, Spearman, and Weighted Rank methods perform well in identifying coordinated transcription factors that control the same biological processes and traits. Surprisingly, the widely used Pearson method is generally less efficient, and so is the Distance Covariance method that can find gene pairs of multiple relationships. Some analyses we did clearly show Pearson and Distance Covariance methods have distinct behaviors as compared to all other six methods. The efficiencies of different methods vary with the data properties to some degree and are largely contingent upon the biological processes, which necessitates the pre-analysis to identify the best performing method for gene association and coexpression network construction.

17 October 2007 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SZS. Lilly Zheng
S. Lilly Zheng
JSJielin Sun
Jielin Sun
YCYu Cheng
Yu Cheng
GLGe Li
Ge Li
FHFang-Chi Hsu
Fang-Chi Hsu
WIWilliam B. Isaacs
William B. Isaacs
Recent studies have provided evidence of associations between genetic markers at human chromosome 8q24 and an increased risk of prostate cancer. We examined whether multiple independent risk variants exist in this region and whether the strength of observed associations differs as a function of disease aggressiveness. We evaluated associations between 18 single-nucleotide polymorphisms (SNPs) in a 1-Mb interval at 8q24 and the risk of prostate cancer among 1563 case patients (1017 of whom had high-grade [Gleason score ≥7] and/or non–organ-confined disease) and 576 control subjects of European American ancestry. Differences in genotype frequencies between case and control subjects were compared using logistic regression analysis, with adjustment for age, and the Wald chi-square test. All statistical tests were two-sided. We identified multiple SNPs in a 50-kb region (referred to as locus 1) that are in linkage disequilibrium with a previously reported risk-associated SNP at 8q24, rs1447295, but were more strongly associated with prostate cancer risk in our study population. We also identified a novel susceptibility SNP, rs6983267, at a second locus (locus 2) that is approximately 70 kb centromeric of rs1447295 and in linkage equilibrium with, and independent of, locus 1. Risk alleles at locus 2 were common in our study population (minor allele frequency ∼50%, 25% homozygous for risk-associated allele). Analysis of the National Cancer Institute’s Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer association study database alone and in combination with our data provided further evidence for this second prostate cancer risk locus; in the combined analysis, the allele frequencies for rs6983267 differed statistically significantly between case patients and control subjects ( P = 1.61 × 10 -9 ). We also identified a third locus at 8q24, approximately 400 kb centromeric to locus 2, that was statistically significantly associated with prostate cancer risk in a combined analysis of our data and CGEMS study data ( P = 6.8 × 10 -4 ). A joint analysis of loci 1 and 2 indicated that 35% of the control subjects carried risk genotypes at one or both these loci; compared with men with the nonrisk genotype at both loci, men with risk genotypes at both loci had an odds ratio of prostate cancer of 2.68 (95% confidence interval [CI] = 1.62 to 4.43) and men with risk genotypes at either locus had an odds ratio of prostate cancer of 1.70 (95% CI = 1.39 to 2.07). Three loci at 8q24 are independent genetic risk factors for prostate cancer.

23 May 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
AMAngela B Mariotto
Angela B Mariotto
EFEric J Feuer
Eric J Feuer
NHNadia Howlader
Nadia Howlader
HCHuann-Sheng Chen
Huann-Sheng Chen
SNSerban Negoita
Serban Negoita
KCKathleen A Cronin
Kathleen A Cronin
The considerable deficit in cancer diagnoses in 2020 due to COVID-19 pandemic disruptions in health care can pose challenges in the estimation and interpretation of long-term cancer trends. Using Surveillance, Epidemiology, and End Results (SEER) (2000-2020) data, we demonstrate that inclusion of the 2020 incidence rates in joinpoint models to estimate trends can result in a poorer fit to the data and less accurate or less precise trend estimates, providing challenges in the interpretation of the estimates as a cancer control measure. To measure the decline in 2020 relative to 2019 cancer incidence rates, we used the percent change of rates in 2020 compared with 2019. Overall, SEER cancer incidence rates dropped approximately 10% in 2020, but for thyroid cancer the decrease was as large as 18% after adjusting for reporting delay. The 2020 SEER incidence data are available in all SEER released products, except for joinpoint estimates of trends and lifetime risk of developing cancer.